19 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutritionRecruitingPhase 32026-10-08NCT07575399
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or ObesityArterial Occlusive Diseases, Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, nutritional disorder, obesity disorder, overnutrition, vascular disorderRecruitingPhase 32026-10-08NCT07037433
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have CirrhosisMetabolic Dysfunction Associated SteatohepatitisRecruitingPhase 32026-10-01NCT06632457
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver FibrosisDigestive System Diseases, Fibrosis, Fibrosis, Liver, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cirrhosis of liver, liver disorderRecruitingPhase 32026-10-01NCT06632444
A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or OverweightBody Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutritionActive, not recruitingPhase 22026-09-28NCT07441252
A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06)Infections, RNA Virus Infections, influenza, respiratory system disorder, respiratory tract infectious disorder, viral infectious diseaseActive, not recruitingPhase 32026-09-17NCT07159763
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic TargetsNutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, type 2 diabetes mellitusActive, not recruitingPhase 22026-08-28NCT07502495
A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of MigraineAcute MigraineRecruitingPhase 32026-08-27NCT07674654
A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Kneearthritic joint disease, arthropathy, musculoskeletal system disorder, osteoarthritis, osteoarthritis, knee, rheumatic disorderRecruitingPhase 22026-08-25NCT06884865
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular EventsInfarction, Necrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cardiovascular disorder, coronary artery disorder, heart disorder, ischemic disease, myocardial infarction, myocardial ischemia, vascular disorderRecruitingPhase 32026-08-21NCT07136012
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migrainebrain disorder, central nervous system disorder, headache disorder, hypnic headache, migraine disorder, nervous system disorderRecruitingPhase 32026-08-20NCT07645924
A Study of Barzolvolimab in Patients With Atopic DermatitisCongenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorderActive, not recruitingPhase 22026-08-11NCT06727552
Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 DiabetesNutritional and Metabolic Diseases, autoimmune disease, diabetes mellitus, endocrine system disorder, glucose metabolism disease, immune system disorder, metabolic disease, type 1 diabetes mellitusActive, not recruitingPhase 32026-07-28NCT06334133
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based TherapyNutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, type 2 diabetes mellitusRecruitingPhase 22026-06-15NCT07502508
A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in AdultsChronic Idiopathic Constipation (CIC)RecruitingPhase 32026-06-04NCT07382167
Evaluation of the ctDNA LUNAR Test in an Average Patient Screening EpisodeDigestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorderActive, not recruitingNot stated2026-05-14NCT04136002
Efficacy and Safety of NVX-CoV2705COVID-19, Coronaviridae Infections, Infections, Nidovirales infectious disease, Orthocoronavirinae infectious disease, RNA Virus Infections, lung disorder, pneumonia, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease, viral pneumoniaActive, not recruitingPhase 42026-05-08NCT07086222
Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing PotentialFemale ContraceptionActive, not recruitingPhase 32026-05-06NCT06672016
Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in AdultsCOVID-19, Coronaviridae Infections, Infections, Nidovirales infectious disease, Orthocoronavirinae infectious disease, RNA Virus Infections, lung disorder, pneumonia, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease, viral pneumoniaActive, not recruitingPhase 2 / Phase 32022-04-06NCT04636697